XML 21 R11.htm IDEA: XBRL DOCUMENT v3.21.2

INVESTMENT IN MARKETABLE EQUITY SECURITIES

3 Months Ended

Jun. 30, 2021

Investment In Marketable Equity Securities

INVESTMENT IN MARKETABLE EQUITY SECURITIES

NOTE 6. INVESTMENT IN MARKETABLE EQUITY SECURITIES

As of March 31, 2020, the Company’s investment in marketable equity securities was comprised of 2,000 shares in Biohaven Pharmaceutical Holding Company Limited (“Biohaven”), a public company listed on the New York Stock Exchange. The Company accounted for its investment in Biohaven as a financial asset classified as fair value through the statement of other comprehensive income (“FVTOCI”).

In August 2020, the Company sold the shares of Biohaven for proceeds of $140,000 resulting in a gain of $72,000.

The following table is a roll-forward of the investment in Biohaven as of June 30, 2021 and 2020:

Schedule of investment in marketable equity securities
		Three Months Ended June 30,
(In thousands)		2021				2020
Balance, beginning of period		$	–			$	68
Unrealized gain on investment			–				78
Balance, end of period		$	–			$	146

X

- Definition

The disclosure of financial assets classified as available for sale. [Refer: Financial assets available-for-sale]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Note Expiry date 2021-01-01
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 10
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2017-en-b&anchor=para_10_e&doctype=Standard&forcepdf=true
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_DisclosureOfAvailableforsaleAssetsExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	ptgef_InvestmentInBiohavenAbstract
Namespace Prefix:	ptgef_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration